Evidence map›Paper›PMID 25645871›Full record

ArticleJournal of nanobiotechnology2015

Investigating the immunomodulatory nature of zinc oxide nanoparticles at sub-cytotoxic levels in vitro and after intranasal instillation in vivo.

Shruti R Saptarshi, Bryce N Feltis, Paul Fa Wright, Andreas L Lopata

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 76 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Zinc intoxication induces ferroptosis in A549 human lung cells.Metallomics : integrated biometal science · 2019
    Article
  12. Inhalation of ZnO Nanoparticles: Splice Junction Expression and Alternative Splicing in Mice.Toxicological sciences : an official journal of the Society of Toxicology · 2019
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Shruti R SaptarshiMolecular Immunology Group, College of Public Health, Medical and Veterinary Sciences, Centre for Biodiscovery and Molecular Development of Therapeutics, James Cook University, Building 21, Molecular Sciences, James Cook Drive, Douglas Campus, Townsville, QLD, 4811, Australia. shruti.saptarshi@jcu.edu.au.
Bryce N FeltisSchool of Medical Sciences, RMIT University, Melbourne, VIC, Australia. bryce.feltis@rmit.edu.au.
Paul Fa WrightSchool of Medical Sciences, RMIT University, Melbourne, VIC, Australia. paul.wright@rmit.edu.au.
Andreas L LopataMolecular Immunology Group, College of Public Health, Medical and Veterinary Sciences, Centre for Biodiscovery and Molecular Development of Therapeutics, James Cook University, Building 21, Molecular Sciences, James Cook Drive, Douglas Campus, Townsville, QLD, 4811, Australia. andreas.lopata@jcu.edu.au.
James Cook University · AUMonash University · AURMIT University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study evaluates the time-dependent pro-inflammatory response of the model human lung epithelial cells (A549) to industrially relevant zinc oxide nanoparticles (ZnO NPs). In terms of toxicity, ZnO-NPs are categorised into the group of high toxicity nanomaterials. However information on pro-inflammatory potential of these NPs at sub-toxic concentrations is limited. Understanding how cellular defense mechanisms function in the presence of sub-cytotoxic concentrations of these NPs is vital. Moreover, there is an urgent need for additional in vivo studies addressing pulmonary toxicity due to accidental inhalation of ZnO NPs.

resultsExposure to sub-cytotoxic ZnO NP concentrations (20 μg/mL) induced significant up-regulation of mRNA for the pro-inflammatory cytokine IL-8 and redox stress marker heme oxygenase-1, along with increased release of IL-8. The highest pro-inflammatory response was recorded after 4 to 6 hr exposure to ZnO NPs over a 24 hr period. Pre-treatment of A549 cells with the sulfhydryl antioxidant N-acetyl cysteine (at 5 mM) resulted in significant reduction of the up-regulation of inflammatory markers, confirming the role of reactive oxygen species in the observed immunomodulatory effects, independent of cytotoxicity. Furthermore, we report for the first time that, intranasal instillation of a single dose (5 mg/kg) of pristine or surfactant-dispersed ZnO NPs can cause pulmonary inflammation, already after 24 hr in a murine model. This was confirmed by up-regulation of eotaxin mRNA in the lung tissue and release of pro-inflammatory cytokines in the sera of mice exposed to ZnO NPs.

conclusionOur study highlights that even at sub-cytotoxic doses ZnO NPs can stimulate a strong inflammatory and antioxidant response in A549 cells. ZnO NP mediated cytotoxicity may be the outcome of failure of cellular redox machinery to contain excessive ROS formation. Moreover exposure to a single but relatively high dose of ZnO NPs via intranasal instillation may provoke acute pulmonary inflammatory reactions in vivo.

Indexed as

AcetylcysteineAdministration, IntranasalAnimalsCell LineDose-Response Relationship, DrugEpithelial CellsFemaleHeme Oxygenase-1HumansImmunologic FactorsInflammationInterleukin-8MAP Kinase Signaling SystemMetal NanoparticlesMice, Inbred BALB CNF-kappa BAcetylcysteineHeme Oxygenase-1HMOX1 protein, humanImmunologic FactorsInterleukin-8NF-kappa BZinc Oxide

Identifiers

PMID25645871
PMCPMC4324663
OpenAlexW2096571675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.